TY - JOUR
T1 - Insulin-like growth factor-I and breast cancer therapy
AU - Ibrahim, Yasir H.
AU - Yee, Douglas
AU - Osborne, Kent
AU - Johnston, Stephen
AU - Arteaga, Carlos
AU - Santen, Richard
PY - 2005/1/15
Y1 - 2005/1/15
N2 - Targeting hormonal and growth factor signaling pathways has proven to be useful in the treatment of breast cancer. In vitro, animal, and epidemiologic evidence provide a rationale for the relevance of the insulin-like growth factor (IGF) system to breast cancer biology. The IGF system has been implicated in promoting mitogenic, metastatic, and antiapoptotic phenotypes in breast cancer. As a consequence of the ability of IGF to promote tamorigenesis, pharmacologic interventions targeting the IGF system are being devised. Such strategies include decreasing ligand production, ligand binding, or receptor activation. In this article, directed anti-IGF strategies and the possible clinical impact of using such therapies for treating breast cancer are discussed.
AB - Targeting hormonal and growth factor signaling pathways has proven to be useful in the treatment of breast cancer. In vitro, animal, and epidemiologic evidence provide a rationale for the relevance of the insulin-like growth factor (IGF) system to breast cancer biology. The IGF system has been implicated in promoting mitogenic, metastatic, and antiapoptotic phenotypes in breast cancer. As a consequence of the ability of IGF to promote tamorigenesis, pharmacologic interventions targeting the IGF system are being devised. Such strategies include decreasing ligand production, ligand binding, or receptor activation. In this article, directed anti-IGF strategies and the possible clinical impact of using such therapies for treating breast cancer are discussed.
UR - http://www.scopus.com/inward/record.url?scp=12144277344&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12144277344&partnerID=8YFLogxK
M3 - Article
C2 - 15701891
AN - SCOPUS:12144277344
SN - 1078-0432
VL - 11
SP - 944s-950s
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 2 II
ER -